Cargando…

Preventive role of carvedilol in adriamycin-induced cardiomyopathy

BACKGROUND & OBJECTIVES: Adriamycin though considered as an effective anticancer drug, leads to irreversible cardiomyopathy (CMP) and congestive heart failure (CHF). The aim of this study was to determine the protective effect of carvedilol in adriamycin (ADR)-induced cardiomyopathy (CMP) in can...

Descripción completa

Detalles Bibliográficos
Autores principales: Jhorawat, Rajesh, Kumari, Savita, Varma, Subhash C., Rohit, Manoj K., Narula, Nidhi, Suri, Vikas, Malhotra, Pankaj, Jain, Sanjay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5393084/
https://www.ncbi.nlm.nih.gov/pubmed/28361826
http://dx.doi.org/10.4103/ijmr.IJMR_1323_14
_version_ 1783229531384971264
author Jhorawat, Rajesh
Kumari, Savita
Varma, Subhash C.
Rohit, Manoj K.
Narula, Nidhi
Suri, Vikas
Malhotra, Pankaj
Jain, Sanjay
author_facet Jhorawat, Rajesh
Kumari, Savita
Varma, Subhash C.
Rohit, Manoj K.
Narula, Nidhi
Suri, Vikas
Malhotra, Pankaj
Jain, Sanjay
author_sort Jhorawat, Rajesh
collection PubMed
description BACKGROUND & OBJECTIVES: Adriamycin though considered as an effective anticancer drug, leads to irreversible cardiomyopathy (CMP) and congestive heart failure (CHF). The aim of this study was to determine the protective effect of carvedilol in adriamycin (ADR)-induced cardiomyopathy (CMP) in cancer patients. METHODS: Patients with lymphoreticular malignancy in whom ADR therapy was planned were randomized into two groups: carvedilol and control. Twenty seven patients each were enrolled in carvedilol and control groups. In the carvedilol group, 12.5 mg once daily oral carvedilol was given during six months. The patients were evaluated by echocardiography before and after chemotherapy. Left ventricular ejection fraction (EF) and systolic and diastolic diameters were calculated. RESULTS: At six months of follow up, six patients in the carvedilol group and five in the control group had died. The mean EF (63.19 vs. 63.88%) and fraction shortening (FS) (34 vs. 34.6) of the carvedilol group were similar at follow up, but in the control group, the mean EF (67.27 vs. 60.82%, P=0.003) and FS (38.48 vs. 34.6, P<0.05) at control echocardiography were significantly lower. In carvedilol group, both systolic and diastolic diameters were not changed, but in control group, systolic diameters were significantly increased compared with basal measures (left ventricular end systolic diameter = 28.26±5.50 mm vs. 31.25± 6.50 mm; P< 0.05). INTERPRETATION & CONCLUSIONS: Prophylactic use of carvedilol in patients receiving anthracycline protected systolic functions of the left ventricle. Carvedilol can be a potential drug which can ameliorate ADR-induced CMP.
format Online
Article
Text
id pubmed-5393084
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-53930842017-05-02 Preventive role of carvedilol in adriamycin-induced cardiomyopathy Jhorawat, Rajesh Kumari, Savita Varma, Subhash C. Rohit, Manoj K. Narula, Nidhi Suri, Vikas Malhotra, Pankaj Jain, Sanjay Indian J Med Res Original Article BACKGROUND & OBJECTIVES: Adriamycin though considered as an effective anticancer drug, leads to irreversible cardiomyopathy (CMP) and congestive heart failure (CHF). The aim of this study was to determine the protective effect of carvedilol in adriamycin (ADR)-induced cardiomyopathy (CMP) in cancer patients. METHODS: Patients with lymphoreticular malignancy in whom ADR therapy was planned were randomized into two groups: carvedilol and control. Twenty seven patients each were enrolled in carvedilol and control groups. In the carvedilol group, 12.5 mg once daily oral carvedilol was given during six months. The patients were evaluated by echocardiography before and after chemotherapy. Left ventricular ejection fraction (EF) and systolic and diastolic diameters were calculated. RESULTS: At six months of follow up, six patients in the carvedilol group and five in the control group had died. The mean EF (63.19 vs. 63.88%) and fraction shortening (FS) (34 vs. 34.6) of the carvedilol group were similar at follow up, but in the control group, the mean EF (67.27 vs. 60.82%, P=0.003) and FS (38.48 vs. 34.6, P<0.05) at control echocardiography were significantly lower. In carvedilol group, both systolic and diastolic diameters were not changed, but in control group, systolic diameters were significantly increased compared with basal measures (left ventricular end systolic diameter = 28.26±5.50 mm vs. 31.25± 6.50 mm; P< 0.05). INTERPRETATION & CONCLUSIONS: Prophylactic use of carvedilol in patients receiving anthracycline protected systolic functions of the left ventricle. Carvedilol can be a potential drug which can ameliorate ADR-induced CMP. Medknow Publications & Media Pvt Ltd 2016-11 /pmc/articles/PMC5393084/ /pubmed/28361826 http://dx.doi.org/10.4103/ijmr.IJMR_1323_14 Text en Copyright: © 2017 Indian Journal of Medical Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Jhorawat, Rajesh
Kumari, Savita
Varma, Subhash C.
Rohit, Manoj K.
Narula, Nidhi
Suri, Vikas
Malhotra, Pankaj
Jain, Sanjay
Preventive role of carvedilol in adriamycin-induced cardiomyopathy
title Preventive role of carvedilol in adriamycin-induced cardiomyopathy
title_full Preventive role of carvedilol in adriamycin-induced cardiomyopathy
title_fullStr Preventive role of carvedilol in adriamycin-induced cardiomyopathy
title_full_unstemmed Preventive role of carvedilol in adriamycin-induced cardiomyopathy
title_short Preventive role of carvedilol in adriamycin-induced cardiomyopathy
title_sort preventive role of carvedilol in adriamycin-induced cardiomyopathy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5393084/
https://www.ncbi.nlm.nih.gov/pubmed/28361826
http://dx.doi.org/10.4103/ijmr.IJMR_1323_14
work_keys_str_mv AT jhorawatrajesh preventiveroleofcarvedilolinadriamycininducedcardiomyopathy
AT kumarisavita preventiveroleofcarvedilolinadriamycininducedcardiomyopathy
AT varmasubhashc preventiveroleofcarvedilolinadriamycininducedcardiomyopathy
AT rohitmanojk preventiveroleofcarvedilolinadriamycininducedcardiomyopathy
AT narulanidhi preventiveroleofcarvedilolinadriamycininducedcardiomyopathy
AT surivikas preventiveroleofcarvedilolinadriamycininducedcardiomyopathy
AT malhotrapankaj preventiveroleofcarvedilolinadriamycininducedcardiomyopathy
AT jainsanjay preventiveroleofcarvedilolinadriamycininducedcardiomyopathy